GleamWall
中文EN

AEON AEON Biopharma, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.51M$2.94M$2.03M$1.61M$597,000$1.06M$825,000$3.04M
SG&A expense$2.99M$2.99M$3.90M$3.89M$1.93M$3.26M$3.12M$2.63M
Operating income-$4.48M-$5.92M-$5.93M-$5.51M-$2.49M-$4.34M-$462,000-$2.32M
Pretax income$2.46M-$1.16M-$11.79M-$37.14M-$4.54M-$6.64M$9.10M$2.08M
Net income$2.46M-$1.16M-$11.79M-$37.14M-$4.54M-$6.64M$9.10M$2.08M
EBITDA-$4.47M-$5.90M-$5.91M-$5.49M-$2.47M-$4.32M-$443,000-$2.30M
EPS (basic)0.01-0.02-0.29—-0.39-0.602.28—
EPS (diluted)0.01-0.02-0.29—-0.39-0.602.28—
Weighted avg. shares (diluted)89.96M50.53M40.61M—11.63M11.09M3.98M—
Balance sheet
Cash & equivalents$11.42M$3.43M$6.24M$3.01M$5.93M$8.44M$10.45M$13,000
Current assets$12.56M$3.99M$6.62M$3.40M$7.41M$10.26M$12.32M$1.59M
PP&E, net$58,000$123,000$142,000$162,000$181,000$200,000$220,000$235,000
Total assets$14.13M$5.91M$8.63M$5.56M$8.73M$11.66M$13.80M$3.14M
Current liabilities$4.57M$7.34M$6.67M$6.90M$8.23M$9.13M$8.64M$14.15M
Total liabilities$11.74M$21.27M$25.38M$60.59M$28.61M$27.51M$25.12M$31.71M
Shareholders' equity$2.39M-$15.36M-$16.75M-$55.03M-$19.87M-$15.85M-$11.32M-$28.57M
Shares outstanding59.08M26.31M25.30M12.11M11.64M11.54M10.54M555,511
Cash flow statement
Operating cash flow-$5.72M-$3.70M-$2.64M-$4.71M-$2.60M-$2.09M-$7.91M-$621,000
Capital expenditure———$0$0$0$4,000—
Free cash flow———-$4.71M-$2.60M-$2.09M-$7.91M—
Investing cash flow———$0$0$0-$4,000—
Financing cash flow$13.72M$886,000$5.87M$1.79M$84,000$84,000$18.35M$97,000
Depreciation & amortization$15,000$20,000$19,000$20,000$19,000$20,000$19,000$23,000
Stock-based compensation$1.60M$1.90M$1.93M$1.59M$1.00M$1.70M$1.73M$1.34M

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.